



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/630,330
Filing Date	7/30/2003
First Named Inventor	Antich, Peter P.
Art Unit	3736
Examiner Name	
Attorney Docket Number	UTSW:1041

Sheet	1	of	2
-------	---	----	---

U.S. PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
/M		US-20020104370	08-08-2002	Steger, et al.	
		US-20030013956	01-16-2002	Michaeli	
		US-4,947,851	08-14-1990	Sarvazyan, et al.	
		US-5,038,787	08-13-1991	Antich, et al.	
		US-5,197,475	03-30-1993	Antich, et al.	
		US-5,228,445	07-20-1993	Pak, et al.	
		US-5,042,492	08-27-1991	Dubut	
		US-5,230,621	07-27-1998	Jacoby	
		US-5,284,143	02-08-1994	Ratner	
		US-5,526,815	08-18-1996	Granz, et al.	
		US-5,772,596	06-30-1998	Forfitt, et al.	
		US-5,806,520	09-15-1998	Berger, et al.	
		US-5,810,731	09-22-1998	Sarvazyan, et al.	
		US-5,873,845	02-23-1998	Cline, et al.	
		US-6,012,779	01-11-2000	Morris	
		US-6,088,538	05-30-2000	Alleyne	
		US-6,102,860	08-15-2000	Mooney	
		US-6,221,019	04-24-2001	Kantorovich	
		US-6,322,507	11-27-2001	Passi, et al.	
		US-6,328,695	12-11-2001	Vammon, et al.	
V		US-6,352,512	03-05-2002	Wilson, et al.	
		US-6,419,648	07-16-2002	Vitek, et al.	
		US-6,537,220	05-25-2003	Friemel, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
/M		WO 0103773 A1	01-18-2001	Hc s, w. x.		

Examiner Signature		Date Considered	9-30-05
--------------------	--	-----------------	---------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²Applicant's unique citation designation number (optional). ³See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10//630,330		
		Filing Date	7/30/2003		
		First Named Inventor	Antich, Peter P.		
		Art Unit	3736		
		Examiner Name			
Sheet	2	of	2	Attorney Docket Number	UTSW:1041

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ANTICH, et al., Measurement of Mechanical Properties of Bone Material In Vitro by Ultrasound Reflection: Methodology and Comparison with Ultrasound Transmission, Journal of Bone and Mineral Research, 1991. 6:417-426.	
		ANTICH, et al., Measurement of Intrastatic Bone Quality In Vivo by Reflection Ultrasound: Correction of Impaired Quality with Slow-Release Sodium Fluoride and Calcium Citrate, Journal of Bone and Mineral Research 1993. 8:301-311.	
		ZERWEKH, et al., Assessment By Reflection Ultrasound Method of the Effect in Intermittent Slow-Release Sodium Fluoride-Calcium Citrate Therapy on Material Strength of Bone, Journal of Bone and Mineral Research 1991 6:239-244.	
		LI, et al., Bisphosphonate Treatment Suppresses Not Only Stochastic Remodeling but Also the Targeted Repair of Microdamage, Calif Tissue Int, 2001, 69:281-286.	
		LIBERMAN, et al., Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis, 1995, The New England Journal of Medicine, Vol. 333 Num. 22.	
		NIH Consensus, Osteoporosis Prevention, Diagnosis, and Therapy, 2001, Vol. 285, No. 6.	
		ODVINA, et al., Severely Suppressed Bone Turnover: A Potential Complication of Alendronate Therapy, 2004, The Journal of Clinical Endocrinology & Metabolism, 90(3):1294-1301.	
		SUSAN OTT, Editorial: Long Term Safety of Bisphosphonates, 2005, A Journal of Clinical Endocrinology & Metabolism, 90(3):1897-1899.	
		PAK et al., Treatment of Postmenopausal Osteoporosis with Slow-Release Sodium Fluoride, 1995, Annals of Internal Medicine, Vol 123, No. 6.	
		RICHER, et al., Reduction in Normalized Bone Elasticity Following Long-term Bisphosphonate Treatment as Measured by Ultrasound Critical Angle Reflectometry, 2005.	

Examiner Signature		Date Considered	9-30-05
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.